Posted on June 1, 2018 by Sitemaster
On May 23, the US Food and Drug Administration apparently approved a new formulation of abiraterone acetate, known as Yonsa®, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, metastatic, Yonsa, Zytiga | 1 Comment »
Posted on July 20, 2017 by Sitemaster
In January and May this year we had noted that a company called Churchill Pharmaceuticals has been developing a different formulation of ultramicron-sized, oral abiraterone acetate (to be called Yonsa™). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, Churchill, formulation, submicron, Yonsa | 2 Comments »
Posted on May 23, 2017 by Sitemaster
In January this year we had mentioned that a company called Churchill Pharmaceuticals was developing a new “submicron” formulation of abiraterone acetate. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abirateone, acetate, Churchill, FDA, Yonsa | 3 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 